Search
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. … As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Reteplase
go.drugbank.com/drugs/DB00015ApprovedInvestigationalWithdrawnRetavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. … Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA.
Products: RAPILYSIN 10 U IV ENJ. ICIN STERIL LIYOFILIZE TOZ ICEREN FLAKON, 2 ADETErdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine has been shown to be safe and well tolerated in clinical trials. … Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier
Avapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]
Categories: MATE 2-K InhibitorsV24343
go.drugbank.com/drugs/DB05201InvestigationalThe anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Levonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
Mixtures: Carbocaine with Neo-Cobefrin, Carbocaine with Neo-CobefrinSynonyms: Neo-cobefrinBetazole
go.drugbank.com/drugs/DB00272ApprovedA histamine H2 agonist used clinically to test gastric secretory function.
MK-0773
go.drugbank.com/drugs/DB16244InvestigationalMK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Betaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.